The human CYP1A1 gene is regulated by the aryl hydrocarbon receptor (AhR), and induction of CYP1A1 is known to play an important role in xenobiotic metabolism. To examine the regulation of human CYP1A1 in vivo, we created a transgenic mouse strain (Tg-CYP1A1 GFP ) expressing a chimeric gene consisting of the entire human CYP1A1 gene (15 kb 
Exposure of mice to classical aryl hydrocarbon receptor (AhR) ligands, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or any of the family of polycyclic aromatic hyrdrocarbons like benzo [a] pyrene (B[a]P), results in activation of the AhR (Okino et al., 1992; Tukey et al., 1982) and induction of selective target genes such as those represented by the family of CYP1 proteins (Nelson et al., 1996) . The transcriptional mechanism of CYP1 induction begins with ligand binding to the AhR and culminates in translocation to the nucleus where the AhR dimerizes with the aryl hydrocarbon receptor nuclear translocator (Arnt) (Hoffman et al., 1991; Reyes et al., 1992) . The AhR/Arnt complex binds to highly conserved DNAenhancer sequences known as xenobiotic response elements (Fujisawa-Sehara et al., 1986; Gonzalez and Nebert, 1985) , resulting in the propagation of the induction signal to the promoter region, alteration of chromatin structure (Okino and Whitlock, 1995; Wu and Whitlock, 1992) and subsequent enhanced gene expression.
Induction of the CYP1A family of proteins, in particular CYP1A1, is a hallmark of exposure to combustion products and other environmental contaminants that activate the AhR. Cell-based assays expressing portions of the CYP1A1-promoter region (Anderson et al., 1995; Postlind et al., 1993) or dioxinresponsive elements (El-Fouly et al., 1995; Nagy et al., 2002; Yueh et al., 2005) fused to reporter genes have been used to screen for potential AhR ligands. These cell-based assays are sensitive, and for the most part can be used to identify agonists/ antagonists capable of interacting with the AhR. To complement this approach, transgenic mice expressing reporter genes driven by AhR-enhancer elements have also proven to be useful in equating gene expression patterns when mice have been exposed to AhR ligands (Campbell et al., 1996; Galijatovic et al., 2004) . Based upon the route of administration, induction of reporter gene activity in vivo not only is the end result of AhR activation but also reflects the contribution of circulating and activated humoral factors toward those processes involved in gene expression. The only potential drawback with the use of reporter gene assays in vivo is that they monitor transcriptional activity that is based upon the steadystate levels of the selected reporter that is being analyzed, and not functional protein.
As an additional tool to examine the regulation of the human CYP1A1 gene, we have generated a transgenic mouse line expressing the human CYP1A1 gene fused in frame to a GFP reporter gene inserted at the last codon located in exon 7 (Tg-CYP1A1 GFP ). This transgenic model serves as a biological tool to explore the mechanisms associated with the regulation and expression of the human CYP1A1 gene in vivo as well as in cultured cells by measuring GFP fluorescence. Since the measurement of induction results from the cellular accumulation of the human CYP1A1 protein, induction is based upon transcriptional response and the steady-state balance of protein accumulation. These mice allow for the visualization of spatial and temporal induction of human CYP1A1 GFP , which can be used as a biomarker for environmental toxicant exposure to substances that serve as AhR ligands.
MATERIALS AND METHODS
Reagents. TCDD was purchased from Wellington Laboratories. B[a]P, 3-methylcholanthrene, b-naphthoflavone (bNF), and an anti-b-actin antibody were purchased from Sigma Aldrich, ST Louis, MO. Human HepG2 cells were purchased from American Type Tissue Culture (http://www.atcc.org/) and the hepa1c1c7 cells were provided by Dr Oliver Hankinson University of California Los Angeles. The antihuman CYP1A1 antibody (Soucek et al., 1995) was kindly provided by Dr Fred Guengerich (Vanderbilt University) and the antihuman UGT1A1, UGT1A4, and UGT1A6 antibodies (Chen et al., 2005; Ritter et al., 1999) from Dr Joseph Ritter (Virginia Commonwealth University). All other products are referenced by the company name and the information can be obtained by an Internet search.
Generation of the CYP1A1
GFP transgenic mice. The human CYP1A1 gene was cloned previously from a human liver genomic library constructed in the replacement vector k- EMBL-3 (McManus et al., 1990 ) and the 15-kb insert removed by SalI digestion followed by cloning into pBluescript II (Stratagene, la Jolla, CA). A selective mutation was made at the stop codon located in exon 7 and the gene subcloned into the pEGFPN2 vector (Invitrogen, Carlsbad, CA), generating a chimeric gene that encoded the full-length CYP1A1 gene fused in frame with the GFP reporter gene (Fig. 1) . The CYP1A1 GFP plasmid DNA was purified from Escherichia coli using Qiagen Plasmid Purification columns (Qiagen, Valencia, CA) followed by linearization with SalI digest. The linearized DNA was microinjected into fertilized CB6F 1 mouse eggs and transplanted into the oviduct of pseudopregnant C57BL/6N mice for the production of transgenic mice. All procedures for the generation of the transgenic mice were carried out by the University of California, San Diego (UCSD) Superfund Transgenic Core Facility. For genotype analysis, DNA from tail clippings was screened by PCR using specific GFP sense 5#-cacatgaagcagcacgactt-3# and antisense 5#-tgctcaggtagtggttgtcg-3# primers. For PCR analysis, DNA was amplified in a 50-ll reaction containing 25 ll of Qiagen Hotstart Master Mix, 5 ng of template DNA, and 0.4lM concentration of each primer. A 15-min activation of the polymerase was carried out at 95°C followed by 30 cycles from 95°C for 30 s to 58°C for 30 s and 72°C for 45 s followed by final extension at 72°C for 7 min. PCR reactions were carried out in a PerkinElmer Life Sciences GeneAmp DNA thermocycler PCR system. From 13 litters and 57 offspring, 12 founders were CYP1A1
GFP positive and five of the founders were bred to produce F 1 offspring. Three out of the five founders had F 1 offspring that produced inducible hepatic CYP1A1 GFP protein following a single intraperitoneal (ip) dose of 16 lg/kg TCDD.
Animal studies. Animal studies were performed in compliance with the rules and regulations for the care and use of laboratory animals from the National Institutes of Health. All animals were 8-12 weeks of age and fed a standard chow diet. TCDD was dissolved in DMSO and given as a single ip dose of 16 lg/kg. B[a]P was dissolved in DMSO:corn oil (50:50 vol/vol) and was given as a single ip dose of 100 mg/kg or 100 mg/kg as an oral dose (po).
Generation of G418-resistant CYP1A1
GFP cells. HepG2 and hepa1c1c7 cells were cultured as previously described (Chen et al., 2003) and transfected with the CYP1A1 GFP expression plasmid and after 48 h were trypsinized and plated at 1/10 volume. The cells were then exposed to media containing 0.8 mg/ml G418 (Invitrogen). After approximately 2-3 weeks, individual colonies were selected and recultured with continued exposure to G418. A number of the expanded colonies were treated with 5nM TCDD for 24 h followed by analysis of induced GFP. In addition, cell populations expressing CYP1A1 GFP was also calibrated by flow cytometry (Chen et al., 2003) . Cells were collected after 24 h following trypsin treatment, washed twice in DPBS (Gibco, Carlsbad, CA) and suspended to a concentration of 1 3 10 6 cells/ml. The suspended cells were acquired on a FACS Calibur flow cytometer and analyzed using CELLQuest software. Conditions for GFP detection were established by setting the excitation maximum at 488 nm, and the emission maximum at 507 nm.
Microsomal protein isolation. Tissues isolated from three mice per treatment group were combined and frozen in liquid nitrogen. Samples were pulverized using a porcelain mortar and pestle under liquid nitrogen. Five volumes of ice-cold 1.15% KCl was added to the pulverized tissue and homogenized using a motorized glass-teflon homogenizer. The tissue homogenate was first centrifuged at 3000 3 g for 10 min at 4°C. The supernatant was removed and then centrifuged at 10,000 3 g for 10 min at 4°C and the resulting supernatant then centrifuged at 100,000 3 g for 60 min at 4°C. The pellet was resuspened in 20% glycerol, 100mM potassium phosphate buffer, pH 7.4 containing 10mM EDTA and 1mM PMSF. FIG. 1. Representation of the CYP1A1-GFP gene construct used to generate the Tg-CYP1A1 GFP mice. The organization of the human CYP1A locus is shown (Corchero et al., 2001) . A lambda-EMBL-3 genomic clone had previously been cloned and characterized (McManus et al., 1990) that contained approximately 9 kb of flanking DNA, as well as exons 1-7 of the CYP1A1 gene. The DNA insert was removed by SalI digestion from the lambda clone and inserted into a pBluescript (Galijatovic et al., 2004) vector and used to generate a new gene construct where the GFP reporter gene was inserted at the stop codon of the CYP1A1 gene. The CYP1A1-GFP plasmid was used for the generation of the Tg-CYP1A1 GFP mice.
HUMAN CYP1A1 GFP EXPRESSION IN TRANSGENIC MICE
Western blot analysis. All Western blots were performed using NuPAGE Bis-Tris polyacrylamide gels as outlined by the supplier (Invitrogen). Protein was heated at 70°C for 10 min in loading buffer and resolved in 4-12% Bis-Tris gels under denaturing conditions (50mM MOPS, 50mM Tris-base, pH 7.7, 0.1% SDS, 1mM EDTA). The resolved protein was transferred onto nitrocellulose membrane using a semidry transfer system. The membrane was blocked with 5% nonfat dry milk in 10mM Tris-HCl, pH 8, 0.15M NaCl, and 0.05% Tween 20 (Tris-buffered saline) for 1 h at room temperature. The membrane was washed in the Tris-buffered saline solution and incubated with primary antibodies in Tris-buffered saline, shaking at 4°C overnight. Membranes were then washed five times with Tris-buffered saline solution and incubated with horseradish peroxidase-conjugated secondary antibodies in Tris-buffered saline solution with 2% nonfat milk for 1 h at room temperature. Membranes were then washed five times with Tris-buffered saline solution and visualized using chemiluminscent reagents according to the manufacturer's instructions (PerkinElmer, Wellesley, MA) followed by exposure to X-ray film.
Isolation and treatment of transgenic mouse primary hepatocytes. Primary hepatocytes were isolated from 8-to 12-week-old mice as previously described (Chen et al., 2005) . Mice were anesthetized by isoflurane inhalation. The portal vein was cannulated and perfused with Hank's Balanced Salt Solution (Ca 2þ free and Mg 2þ free) containing 0.1mM EGTA and 10mM HEPES at pH 7.4 for 5 min at a flow rate of 7 ml/min. The anterior vena cava was cut immediately after the perfusion began to allow for continuous flow of the solution out of the liver. After the 5-min initial perfusion, the perfusate was changed to 20 lg/ml Liberase Blendzyme (Roche Applied Science, Indianapolis, IN) in Hank's Balanced Salt Solution (with Ca 2þ and Mg 2þ ) for 5 min at a flow rate of 7 ml/min. The liver was removed and placed in low-glucose DMEM media, and the hepatocytes were isolated by mechanical dissection followed by filtration through a sterile 70-lm filter. The cells were collected by centrifugation at 50 3 g for 30 s and washed with low-glucose DMEM media. The hepatocytes were cultured in six-well collagen-treated plates (Discovery Labware) in 3 ml of low-glucose DMEM media containing penicillin/ streptomycin and supplemented with 10% fetal bovine serum. Three hours after plating the media was removed and replaced with fresh media and the hepatocytes used for subsequent experiments after a 24-h recovery period. The hepatocytes were treated with various chemicals for 48 h, and the media containing the chemical compounds refreshed after 24 h. For Western blot analysis, hepatocytes were collected and lysed in a buffer containing 0.05M Tris-HCl, pH 7.4, 0.15M NaCl, 0.25% deoxycholic acid, and 1% Nonidet P-40 with a compliment of protease and phosphatase cocktail inhibitors (Sigma Aldrich). After incubation in lysis buffer for 1 h on ice, the supernatant was collected after centrifugation for 20 min in a refrigerated Eppendorf centrifuge at 16,000 3 g, and used directly for Western blot analysis.
Tissue section fluorescence microscopy. Transgenic mice were anesthetized with the general anesthetic, nembutol. The mice were then intracardially perfused with Ringer's solution at a rate of 4 ml/min until the liver was clear of blood, followed by perfusion with 4% paraformaldehyde in PBS. The organs were then removed and placed in 4% paraformaldehyde on ice for 2 h to allow for complete fixation. Each organ was sectioned using a vibratome at 100 lm thickness. Tissue sections were washed 33 with PBS and mounted on glass slides with gelvatol (antifade medium). The slides were stored at 4°C until imaged. Samples were visualized by confocal microscopy using an MRC-1024 system (Bio Rad Laboratories, Hercules, CA) attached to an Axiovert 35M (Zeiss AG) and a 403 NA objective. Excitation illumination was with 488 nm light from a krypton/argon laser. Individual images (1024 3 1024 pixels) were converted to PICT format and merged as pseudo-color RGB images using Adobe Photoshop.
Fluorescence microscopy. Primary hepatocytes were isolated and cultured on collagen-treated plates as previously described. Hepatocytes were treated with the following CYP1A1 inducers: TCDD at 0.1, 1, and 10nM, B[a]P, 3-methylcholanthrene, and bNF at 0.1, 1, and 10lM. Hepatocytes were treated for 48 h and media changed every 24 h with fresh compound. Cells were then imaged using the Axiovert 200 microscope (Zeiss, Ismaning, Germany) with Endow GFP Bandpass filter set.
Measuring tissue fluorescence in microsomal preparations. Fluorescence of 50 lg of microsomal protein from various organs was measured using a Tecan Safire fluorescence plate reader (Tecan, San Jose, CA) in a 96-well UV plate (Costar, Corning, NY). CYP1A1
GFP was excited at 488 nm and emission intensity was measured at 525 nm using an excitation and emission slit widths of 5 nm in a top read mode at room temperature.
Measurement of 7-ethoxyresorfin O-deethylase activity. A marker of CYP1A1/CYP1A2 activity, 7-ethoxyresorufin O-deethylase (EROD) activity, was measured using 20 lg of liver microsomes containing 100mM potassium phosphate buffer (pH 7.4), 5mM MgCl 2 , 8lM 7-ethoxyresorufin and 1mM NADPH. Reactions were incubated for 15 min at 37°C and then terminated by the addition of 100 ll cold methanol. The formation of resorufin was measured fluorometrically with an excitation at 530 nm and emission at 590 nm and normalized to a resorufin standard.
RESULTS

Characterization of CYP1A1
GFP Tissue Expression in Tg-CYP1A1
GFP Mice
We have previously demonstrated that the human CYP1A1 gene could be regulated in CYP1A1N transgenic mice by the identification of TCDD-induced human CYP1A1 in tissues such as liver and lung (Galijatovic et al., 2004) , but not small intestine. In attempts to design a CYP1A1 marker protein that could be identified by fluorescence, a CYP1A1-GFP chimeric gene (CYP1A1 GFP ) was first constructed with the stop codon in exon 7 interrupted and replaced in frame with the GFP gene (Fig. 1) . This new construct contains 9 kb of regulatory sequence, and when stably integrated into human HepG2 or mouse hepa1c1c7 cells produced a TCDD-inducible CYP1A1 GFP fusion protein that could be detected with either an antihuman CYP1A1 antibody or an anti-GFP antibody (Fig. 2) . The anti-CYP1A1 antibody recognizes mouse and human CYP1A1, which can be seen to have slightly different mobilities, as previously shown (Galijatovic et al., 2004) . The increase in CYP1A1 GFP was also represented in the HepG2 cells following a 24-h exposure to TCDD as demonstrated by separation of those cells eliciting fluorescence by flow cytometry (Fig. 2) .
With expression of CYP1A1 GFP demonstrated in tissue culture, the CYP1A1 GFP gene was used to generate transgenic mice (Tg-CYP1A1 GFP ). Following the selection of a transgenic founder line that transmitted the gene, the Tg-CYP1A1 GFP mice were treated with a single ip dose of TCDD and expression of CYP1A1 GFP monitored in microsomes from different tissues. The inducibility of CYP1A1 GFP was first demonstrated in whole liver when a transgenic mouse was treated with TCDD and the liver exposed and imaged under blue light optics (Fig. 3A) . The entire liver was fluorescent green in contrast to the liver from the nontreated transgenic mouse. Isolation of microsomes from TCDD-treated mice followed by fluorometric analysis confirmed a four-to six-fold 100 OPERAÑ A ET AL. increase in liver fluorescence over DMSO-treated Tg-CYP1A1 GFP mice (Fig. 3B) . A two-fold increase in CYP1A1 GFP fluorescence was observed in lung microsomes, while no detectable induction of fluorescence was seen in kidney, small intestine, large intestine, brain, or spleen. When Western blots were conducted, TCDD injection led to the prominent induction of mouse CYP1A1 (mCYP1A1) (Fig. 4) . In addition, the anti-CYP1A1 antibody detected
FIG. 2. Expression of CYP1A1
GFP in mouse and human hepatoma cells following stable transfection of the CYP1A1-GFP gene construct. The CYP1A1-GFP plasmid construct was transfected into either human HepG2 cells or mouse hepa1c1c7 (Hepa) cells and stable clones were selected in the presence of G418 in the culture media. (A) The selected cells were treated with either DMSO (D) or 10nM (TCDD) for 48 h, and whole-cell lysates were used in Western blot analysis to identify CYP1A1 GFP expression. Western blots were analyzed with an anti-CYP1A1 or an anti-GFP antibody. The anti-CYP1A1 antibody identified expressed mouse CYP1A1 (mCYPIAI) and human CYP1A1 (hCYPIAI), as indicated by the arrows, as well as induced CYP1A1
GFP . (B) Stable CYP1A1
GFP HepG2 cells were treated for 24 h with TCDD and the cells subjected to flow cytometry. Positive GFP-expressing cells were identified.
FIG. 3. Analysis of GFP fluorescence in tissues. Tg-CYP1A1
GFP mice were treated with a single ip injection of TCDD or DMSO. (A) Mice were sacrificed and the liver was exposed for imaging using a whole animal fluorescence imaging system to visualize CYP1A1 GFP in liver. (B) Tissues were combined according to treatment groups (n ¼ 3), and microsomes were prepared from each tissue. One hundred micrograms of protein was resuspended in PBS, and fluorescence was measured using a fluorometer, excitation ¼ 488 nm and emission ¼ 525 nm.
FIG. 4. Induction of CYP1A1
GFP in transgenic mice following treatment with TCDD. Tg-CYP1A1 GFP mice (n ¼ 3 per group) were treated ip with DMSO or 16 lg/kg TCDD for 24 h. Tissues were pooled and microsomes prepared. For Western blot analysis, 25 lg of protein from each sample was used. Separate Western blots were generated for analysis with the anti-GFP and anti-CYP1A1 antibodies. GFP were also detected in microsomes from lung tissue.
Fluorescence Analysis of Tissue Sections of Liver and Lung
The Western blot and fluorometry data indicated that CYP1A1 GFP was inducible in both the liver and the lung. Tissue sections were then performed on these tissues to determine the cellular localization of the GFP fluorescence. Following injection of a single ip dose of TCDD (16 lg/kg) for 24 h, the mice were whole body perfused and fixed with 4% formaldehyde. Tissues were sectioned at 100 lm thickness and imaged using confocal microscopy with excitation at 488 nm with a krypton/argon laser. Very little background fluorescence was observed in liver and lung tissue from Tg-CYP1A1 GFP mice that were treated with DMSO (Figs. 5A and 5C). In mice that were treated with TCDD, abundant GFP fluorescence was observed in liver hepatocytes, signifying that activation of the AhR led to adequate expression of CYP1A1 GFP (Fig. 5B ). When lung tissue was examined, primary fluorescence was noted in a population of cuboidal-shaped cells, signifying that induction in the lung is restricted to a selective cell type that morphologically resembles Clara cells (Fig. 5D ).
CYP1A1 GFP Expression in Primary Hepatocytes
Since TCDD treatment demonstrated induction of CYP1A1 GFP in liver tissue, experiments were conducted to examine the potential for induction in primary hepatocytes. To initiate these experiments, primary hepatocytes were isolated from Tg-CYP1A1 GFP mice and cultured on collagencoated tissue culture plates. The cells were treated with 10nM TCDD for 8, 24, and 48 h and fluorescence images were captured following each treatment with a Zeiss inverted microscope using a GFP filter set. As shown in Figure 6 , DMSO-treated hepatocytes exhibited very little background fluorescence. At 8 h of TCDD exposure, slight GFP fluorescence was observed compared to the DMSO-treated hepatocytes. At 24 h, the GFP signal increased and maximum GFP fluorescence was observed following 48 h of exposure to TCDD.
To determine the sensitivity of CYP1A1 GFP induction with other AhR agonists, primary hepatocytes were isolated from Tg-CYP1A1 GFP mice and the cells treated with agents known to activate the AhR. After 48 h of exposure, the cells were
GFP expression in primary hepatocytes after TCDD treatment. Primary hepatocytes were isolated from transgenic mice and treated with 10nM TCDD or DMSO over a 48-h time course. Primary hepatocytes were imaged using an inverted fluorescence microscope with excitation ¼ 488 nm and emission at 525 nm. GFP mice were treated with 16 lg/kg TCDD or DMSO for 24 h. Intracardial perfusion was performed with 13 PBS, followed by 4% formaldehyde. Liver and lung were dissected and fixed in 4% formaldehyde overnight at 4°C. Tissues were sliced at 100 lm thickness using a vibratome and mounted onto slides. Samples were imaged using a confocal microscope with excitation ¼ 488 nm and emission ¼ 525 nm. Panels A and C are DMSO-treated liver and lung sections, respectively. Panels B and D are TCDD-treated liver and lung sections, respectively. collected, resuspended in PBS, and fluorescence was measured using a 96-well fluorometer (Fig. 7A) . TCDD induced maximal fluorescence at 0.1nM (lower concentrations were not tested), while B[a]P and 3-methylcholanthrene (3MC) induced fluorescence at 1lM and b-Naphthoflavone (bNF) facilitated induction at 10lM. The induced fluorescence profiles matched induction of CYP1A1 GFP as determined by Western blot analysis (Fig. 7B) . In addition, the induction of CYP1A1 GFP with each of the AhR agonists was paralleled by increases in mCYP1A1. These results confirm that Tg-CYP1A1
GFP hepatocytes can be used to examine the potential of chemicals and xenobiotics to induce human CYP1A1.
Induction and Function of CYP1A1 GFP following Oral Administration of B[a]P
Following the ip injection of B[a]P into Tg-CYP1A1 GFP mice, induction of CYP1A1 GFP was apparent by detection of the fusion protein by Western blot analysis as well as fluorescence in microsomal preparations. However, the ip administration of drugs and other xenobiotics is not representative of normal routes of exposure. To examine the effects of oral B[a]P administration on CYP1A1 GFP induction, Tg-CYP1A1 GFP mice received B[a]P (100 mg/kg) every day for 3 days and tissues were collected 24 h after the last dose.
Western blots using liver and lung microsomal preparations demonstrated induction of CYP1A1 GFP in these tissues as indicated with the anti-GFP and anti-CYP1A1 antibody (Fig. 8) . It was interesting to note that minimal induction of mCYP1A1 was observed in liver microsomes after oral administration of B[a]P although induction was observed in lung. Since mCYP1A1 was not detected in liver at an oral dose of 100 mg/kg, the appearance of CYP1A1 GFP at this dose leads us to speculate that the induction of fluorescence in these mice may be a more sensitive indicator of AhR activation than induction of mCYP1A1.
The preferential induction of liver CYP1A1 GFP by oral B[a]P administration led us to examine the contribution of induced CYP1A1 GFP toward EROD activity, a relatively specific microsomal monooxygenase activity that has been attributed to expressed CYP1A1/1A2 (Fisher et al., 1992; Guo et al., 1994; Sandhu et al., 1994) . When we measured liver microsomal EROD activity from wild type (WT) litter mates treated orally with B[a]P, there was a two-to three-fold induction of activity in microsomes (Table 1 ). Since we were unable to detect by immunoblot-induced mCYP1A1 (Fig. 8) , this activity may result from mild induction of a faster mobility band observed by Western blot analysis (Fig. 8, lane 4) , which may correspond to mCYP1A2. However, when EROD activity was measured in liver microsomes from Tg-CYP1A1 GFP mice given B[a]P by oral administration, EROD activity was induced 8-to 10-fold over control (Table 1) , and was comparable to those GFP mice (n ¼ 3) for each treatment group were treated 16 lg/kg TCDD by the ip route. For B[a]P treatment, 100 mg/kg B[a]P was injected ip for 3 days, or 100 mg/kg B[a]P was administered by po for 3 days. Control mice received 100 ll of DMSO/corn oil (50:50 vol/vol) each day for 3 days. On the fourth day, the animals were sacrificed and the liver and the lung from each animal were collected. The organs from each treatment group were combined and microsomes were prepared. For each Western blot, 20 lg of microsomal protein was used. The anti-CYP1A1 and anti-GFP antibodies were used to detect mCYP1A1 and CYP1A1 GFP , respectively. Loading of protein was analyzed by Western blot using an anti-b-actin antibody.
FIG. 7. Dose-dependent induction of CYP1A1
GFP in primary hepatocytes using various AhR ligands. Primary hepatocytes from Tg-CYP1A1 GFP mice were isolated and cultured for 24 h. Hepatocytes were treated for 48 h with three different concentrations of inducers indicated as low, medium, and high. The inducers were TCDD (0.1, 1.0, and 10nM), B[a]P (0.1, 1.0, and 10lM), 3MC at (0.1, 1.0, and 10lM) and bNF at (0.1, 1.0, and 10lM). (A) Cells were collected and resuspended in 13 PBS, and fluorescence was measured using a fluorometer with excitation ¼ 488 nm and emission ¼ 525 nm. (B) At the highest concentration of each treatment, cells were collected and total cell lysate was used for Western blot analysis using anti-GFP and -CYP1A1 antibodies. GFP by oral B[a]P administration is responsible for the majority of the induced EROD activity in transgenic mice, confirming that the fusion protein is functional.
As another means to examine the potential of oral B[a]P treatment to induce other xenobiotic metabolizing proteins, we examined the expression of several human UGT1A proteins in transgenic mice (Tg-UGT1) that express the human UGT1 locus. In Tg-UGT1 mice, functional expression of all nine human UGTs have been demonstrated, with expression of the genes targeted by activation of xenobiotic receptors such as the pregnane X-receptor, the liver X-receptor alpha, and the AhR (Chen et al., 2005; Verreault et al., 2006) . In previous studies (Chen et al., 2005) , the UGT1A proteins have been shown to be expressed and induced in the GI tract following treatment with TCDD. When Tg-UGT1 mice were treated orally with B[a]P for 3 days, Western blot analysis using microsomes from the small intestine confirmed the induction of human UGT1A1, UGT1A4, and UGT1A6 (Fig. 9) . Interestingly, UGT1A1, UGT1A4, and UGT1A6 were also induced in liver, indicating that adequate concentrations of B[a]P were being absorbed through the portal circulation to the liver resulting in activation of the AhR. These results indicate that oral B[a]P treatment is sufficient to induce human CYP1A1 and UGT1A gene expression in liver, but has limited potential to induce mCYP1A1 in liver.
DISCUSSION
The development of transgenic mouse strains that express human genes provides a novel opportunity to examine the regulatory properties of the genes but also the functional role of the regulated gene product. The current study demonstrates that the entire human CYP1A1 gene spliced to a reporter GFP gene produces a functional and inducible CYP1A1 GFP fusion protein in transgenic mice. Isolation of primary hepatocytes from Tg-CYP1A1
GFP mice provides a sensitive biological tool to quantitate CYP1A1 gene induction through the simple and rapid measurement of induced GFP fluorescence. Following the ip treatment of Tg-CYP1A1 GFP mice with TCDD, induced fluorescence was observed primarily in liver and lung tissue. This corresponded with the induction of human CYP1A1 as previously demonstrated in transgenic mice that express only the human CYP1A1 gene (Galijatovic et al., 2004) . Similar induction patterns were seen when mice were treated by oral administration with B[a]P, confirming that absorption of AhR ligands into circulation through the oral cavity serves as an efficient mechanism to examine induction of the CYP1A1 gene in these tissues. In addition, CYP1A1 GFP fluorescence was not observed in the gastrointestinal tract or kidney, similar to the expression patterns of the human CYP1A1 gene and CYP1A1-luciferase gene in transgenic mice expressing these DNA constructs (Galijatovic et al., 2004) . Thus, consistency in the induction pattern of the human CYP1A1 genes in different transgenic strains is corroborated.
One of the unique aspects of undertaking regulatory gene experiments in transgenic mice is the ability to examine expression patterns in different tissues following routes of administration that contrast those to classical treatment regimes such as the administration of xenobiotics by the oral (Chen et al., 2005) mice were treated by po with 100 mg/kg B[a]P for 3 days. Control Tg-UGT1 mice received 100 ll of a solution of DMSO/corn oil (50:50 vol/vol) for 3 days. Livers and small intestines (SI) were isolated and microsomes were prepared. For Western blot analysis, 20 lg of protein was loaded into each lane. Human liver microsomes (HLM) were used as a positive control for UGT1A expression. Human-specific anti-UGT1A1, -UGT1A4, and -UGT1A6 antibodies were used to detect isoform-specific UGTs.
